A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT03136497 · TERMINATED
Trial details
- NCT number
- NCT03136497
- Sponsor
- Hackensack Meridian Health
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-05
- Primary completion
- 2020-11-09
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.